# Jieyi Wang

> Jieyi Wang is the founder, chairman and CEO of Lyvgen Biopharma, an antibody scientist whose career runs from 22 years in oncology R&D at Abbott and AbbVie to building a cross-border biotechnology company around conditional immune-receptor agonism. With degrees from Shanghai Medical University and Stony Brook University, Wang has helped advance antibody programs into clinical development, co-authored research on MET-targeted and multifunctional antibodies, and built Lyvgen’s xLinkAb platform and oncology pipeline.

- **Role:** Founder, Chairman and CEO at Lyvgen Biopharma
- **Organizations:** Lyvgen Biopharma, AbbVie, Abbott
- **Education:** B.S., Shanghai Medical University (now part of Fudan University), M.S., Shanghai Medical University (now part of Fudan University), Ph.D. in Molecular and Cellular Pharmacology, Stony Brook University
- **Known for:** Founded Lyvgen Biopharma in 2016 and built its xLinkAb antibody platform and clinical pipeline., Spent 22 years in oncology R&D at Abbott and AbbVie and led teams that advanced antibody drugs into clinical development., Contributed to the development and publication of work on telisotuzumab vedotin (ABBV-399), a MET-targeted antibody-drug conjugate.

## Career timeline

- **1994-2012** — Worked in oncology research and development at Abbott, ultimately serving as Senior Group Leader and Associate Research Fellow.
- **2013-2016** — Held senior oncology R&D roles at AbbVie, including Senior Principal Research Scientist.
- **2016** — Founded Lyvgen Biopharma and became its chairman and CEO.
- **2019** — Lyvgen began a Phase 1 study of LVGN6051 as a single agent and in combination therapy.
- **2020** — Lyvgen announced a clinical-trial collaboration with MSD and opened a therapeutic-antibody CMC center in Suzhou.
- **2021** — Lyvgen completed Series C financing led by IDG Capital and dosed the first participant in a Phase 1 study of LVGN7409.
- **2022** — Lyvgen published a review on FcγRIIB cross-linking and TNFRSF agonist antibodies.
- **2024** — Two exlinkibart clinical studies were selected for the ASCO Annual Meeting, and Wang co-authored an abstract on a Phase 1b/2 soft-tissue-sarcoma study.
- **2026** — Was listed as a BIOCHINA 2026 speaker on trispecific T-cell engagers; a U.S. anti-CD40 patent naming him as an inventor was granted.

## Achievements

- Founded Lyvgen Biopharma in 2016 and built its xLinkAb antibody platform and clinical pipeline.
- Spent 22 years in oncology R&D at Abbott and AbbVie and led teams that advanced antibody drugs into clinical development.
- Contributed to the development and publication of work on telisotuzumab vedotin (ABBV-399), a MET-targeted antibody-drug conjugate.
- Is named as an inventor on Lyvgen patents covering immune-response modulation and anti-CD40 binding molecules.
- Co-authored peer-reviewed research on MET-targeted antibodies, multifunctional antibodies and immune-oncology mechanisms.

## Latest updates

- **2026-06** — U.S. Patent No. 12,662,543, covering anti-CD40 binding molecules and bispecific antibodies and naming Jieyi Wang and Yi Wu as inventors, was granted to Lyvgen Biopharma Holdings Limited.
- **2026-03** — BIOCHINA 2026 listed Wang as a speaker on B7H3×CD3×PD-L1 trispecific T-cell engagers in cancer immunotherapy.
- **2024-05** — Two studies of exlinkibart (LVGN6051) were selected for presentation at the 2024 ASCO Annual Meeting.
- **2024-03** — Lyvgen announced Chinese approval for a Phase 2 clinical application evaluating LVGN6051 in combination therapy for head and neck squamous cell carcinoma.

## Links

- Website: https://www.lyvgen.com/management
- LinkedIn: https://www.linkedin.com/in/jieyi-wang-3b8b591a

---

Profile page: https://yespress.io/jieyi-wang
Published by YesPress — https://yespress.io
Last updated: 2026-08-18